데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
610798-31-7C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1QQLKULDARVNMAL-UHFFFAOYSA-N610798-31-7DTXSID20209952CHEMBL2087361안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Icotinib is also known as ConMana. It is a highly selective, first-generation inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TKI), whose mutation and overexpression is involved in many kinds of cancer. Icotinib is a quinazoline derivative that binds reversibly to the ATP binding site of the EGFR protein, being capable of blocking the signal transduction cascade. It is currently under investigation for its treatment efficacy on the EGFR+ Non-small cell lung cancer.
용도Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with IC50 of 5 nM.
일반 설명Class: receptor tyrosine kinase Treatment: NSCLC Oral bioavailability = 52%Elimination half-life = 5.5 h
불러오는 중…
불러오는 중…
불러오는 중…